A New Tumor Marker for Pancreatic Cancer?

Article

Researchers at Mayo Clinic evaluated the use of secreted proteins as markers of pancreatic ductal adenocarcinoma.

Pancreatic cancer often is diagnosed at a later stage of disease. Ideally, identification of a tumor marker or other early detection technique would reduce deaths from pancreatic cancer.

Researchers at the Mayo Clinic and University of Pennsylvania identified secreted proteins and tested a subset of these proteins to determine if they might be markers of pancreatic ductal adenocarcinoma (PDAC). In a phase I study, a phase 2a validation study, and a second phase 2b study (746 blood samples in total), concentrations of plasma thrombospondin-2 (THBS2) were able to discriminate resectable stage I cancer as readily as stage III and IV pancreatic tumors. THBS2 plasma concentrations combined with those for CA 19-9 increased the ability to distinguish PDAC from pancreatitis, and may improve the early detection of PDAC.

The study findings are available at here.

Related Videos
Karyn Goodman
Expert in oncology
Expert in oncology
Experts in oncology
Expert in oncology
Expert in oncology
Expert in oncology
Expert in oncology
Experts in oncology
Related Content
© 2024 MJH Life Sciences

All rights reserved.